These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25691376)

  • 1. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe.
    Duck A; Pigram L; Errhalt P; Ahmed D; Chaudhuri N
    Adv Ther; 2015 Feb; 32(2):87-107. PubMed ID: 25691376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment.
    Russell AM; Ripamonti E; Vancheri C
    BMC Pulm Med; 2016 Jan; 16():10. PubMed ID: 26762154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Anderson A; Shifren A; Nathan SD
    Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Poletti V; Ravaglia C; Tomassetti S
    Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
    Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
    BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
    Lancaster LH; de Andrade JA; Zibrak JD; Padilla ML; Albera C; Nathan SD; Wijsenbeek MS; Stauffer JL; Kirchgaessler KU; Costabel U
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29212837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
    Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
    Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
    Potts J; Yogaratnam D
    Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
    Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
    Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
    Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
    Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
    Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
    J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
    Selvaggio AS; Noble PW
    Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.